<DOC>
	<DOCNO>NCT02774772</DOCNO>
	<brief_summary>The investigator collect range physiological , behavioural environmental data use current mHealth home-monitoring system , environmental database patient characteristic , determine extent asthma control occurrence asthma exacerbation predict .</brief_summary>
	<brief_title>The Use Home-monitoring mHealth Systems Predict Asthma Control Occurrence Asthma Exacerbations</brief_title>
	<detailed_description>This observational study occur alongside participant ' normal asthma care . Participants ask attend normal GP hospital appointment , continue take medication determine usual healthcare team . In addition normal care , participant attend induction visit complete 12-month home-monitoring period 2 phase : - Phase 1 : one-month period daily monitoring asthma - Phase 2 : eleven-month period weekly monitoring asthma . Patients invited 2-week period daily monitor 2-9 month Phase 2 . The purpose second phase daily monitoring assess influence seasonality ( different season ) patient 's asthma . 0 xxxx 1 -- -- -- 2 -- -- -- 3 -- -- -- 4 yy -- 5 -- -- -- 6 -- -- -- 7 -- -- -- 8 -- -- -- 9 -- -- -- 10 -- -- -- 11 -- -- - 12 Figure 1 . Schematic study design . 0 1 2.. , month ; xxxx , first series 4 week daily monitoring ; -- -- -- 11 month weekly monitoring ; yy -- , example second series 2 week daily monitor month 5 ( time 2 weekly phase randomise month 2-9 ) . A variety measurement make induction visit 12-month home-monitoring period , detail : Induction visit Demographics - Age ( yr ) , gender , nationality , ethnicity , body mass ( kg ) , height ( cm ) , body mass index ( BMI ) , comorbidities , medication , previous moderate severe asthma exacerbation precede 12 month , previous severe asthma exacerbation require hospital attendance / admission ( No precede 12 month ) , number intensive care admission asthma ( ever ) , smoke history social economic status . Questionnaires - Asthma control assess Asthma Control Questionnaire ( ACQ ) . [ A patient 's asthma control status classify Controlled ( ACQ≤0.75 ) , Partly Controlled ( 0.75 &lt; ACQ≤1.5 ) Uncontrolled ( ACQ &gt; 1.5 ) ] . - The typical diet participant assess via Global Allergy Asthma European Network ( GA2LEN ) food frequency questionnaire . - Sinusitis/rhinoconjunctivitis determine via Sino-Nasal Outcome Test 22 ( SNOT 22 ) - Anxiety depression determine via hospital anxiety depression score ( HADS ) - Characteristics health direct behaviour self-monitoring determine use Health education impact Questionnaire ( HeiQ ) - Mini-Asthma Quality Life Questionnaire ( mini-AQLQ ) Clinical test - Atopic status determine via previous skin-prick test blood test result . ( If patient 's atopic status unknown , standard skin-prick test blood test conduct ) . - The diagnosis asthma verify via previous test result , use one following ; bronchodilator reversibility test , one-week peak flow monitor bronchial challenge test . ( If patient 's asthma diagnosis verify one test list , may perform screen visit ) - Lung function ( spirometry ) conduct accord ERS guideline - Airways inflammation determine level Fractional exhale Nitric Oxide ( FeNO ) accord establish guideline - Exhaled Breath Temperature , measure X-halo device Phase 1 ( first 4-week daily monitoring ) The measurement Phase 1 collect first 4 week monitoring , self-administered participant . Measurements occur continuously , daily , weekly less frequent , specify : Questionnaires - Daily , Asthma Control Diary ( ACD ) - Daily , online medication diary - Weekly , assessment occurrence exacerbation , determine custom questionnaire . - Monthly , mini Asthma Quality Life Questionnaire ( mini-AQLQ ) - Sinusitis determine via SNOT 22 end first 4-week daily monitor - Technology acceptance via ASQ end first 4-week daily monitoring 25 Physiological monitoring - Continuous data collection , via wearable sensor - Pulse , exercise level via Fitbit HR wristband - Medication usage adherence via Smartinhaler device subset 60 participant - Measurement breath rate via Spire device - Daily , twice daily home spirometry ( FEV1 ) via Piko-1 device - Daily , twice-daily Fractional exhale Nitric Oxide ( FeNO ) via NIOX-VERO device subset 60 participant - Daily , twice-daily Exhaled Breath Temperature ( EBT ) via X-halo device , subset 60 participant Environmental - Retrospective collection environmental condition patient home work address , include : - Ozone ( O3 ) - air pollution ( PM10 , PM2.5 ) - ambient temperature - Nitrous oxide ( NO2 ) - Sulphur dioxide ( SO2 ) - Weather condition - Mean temperature - Humidity - Pollen count Phase 2 ( month 2-12 ) The measurement Phase 2 occur continuously , weekly less frequent , specify . The weekly measurement occur fix day week , determine participant convenience , measurement self-administered participant . Questionnaires - Weekly online Asthma Control Questionnaire - Weekly assessment occurrence exacerbation , determine custom questionnaire . - Weekly , medication diary ( custom make questionnaire ) - Monthly mini Asthma Quality Life Questionnaire ( mini AQLQ ) - Monthly , Sinus symptoms determine via SNOT 22 questionnaire - Technology acceptance via ASQ 6 12 month - Global Allergy Asthma European Network ( GA2LEN ) food frequency questionnaire complete end study . Physiological monitor - Continuous data collection , via wearable sensor - Pulse , exercise level via Fitbit HR wristband - Medication usage adherence via Smartinhaler device subset 60 participant - Measurement breath rate via Spire device - Weekly , home spirometry ( FEV1 ) via Piko-1 - Weekly , Fractional exhale Nitric Oxide ( FeNO ) NIOX-VERO subset 60 participant - Weekly , Exhaled Breath Temperature ( EBT ) X-halo , subset 60 participant Environmental - Retrospective collection environmental condition patient home work address , detail . A second series daily monitoring ( described phase 1 ) perform two week period , randomise 2 9 month .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<criteria>1 . Doctorsdiagnosis asthma confirmation asthma one follow test medical note : ) Reversibility 12 % 200ml spirometry follow administration bronchodilator medication ii ) Peak flow monitor one week iii ) Positive bronchial challenge 2 . BTS asthma treatment step 24 , minimum 6 month previous year 3 . A course oral prednisone minimum three day , emergency department visit/hospitalisation asthma , previous twelve month . Or currently experience uncontrolled asthma ( base result Asthma Control Questionnaire ) 1 . Comorbidities cause overlap symptom breathlessness , wheeze , cough interfering chronic condition ( example symptomatic chronic respiratory disease , cardiac failure etc. ) . 2 . Unable understand English Dutch , appropriate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
</DOC>